A $4 billion-a-year drug linked to cancer? A company denying it? Well, it’s the same ole’ thing as Sanofi denies that it’s drug used to treat diabetes (the insulin Lantus) is linked to cancer.
A new study done by Swedish researchers looked at the medical records of 23,000 people in the southwest of the country in an attempt to find common links to cancer, they found an apparent doubling of cancer risk in those taking Sanofi’s long-acting insulin Lantus. The company, of course, denies it all. Stay tuned.